News
Craig-Hallum initiated coverage of Actuate Therapeutics (ACTU) with a Buy rating and $21 price target Stay Ahead of the Market: Discover ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback